ArticleFrontiers in pharmacology2025
Effect of itraconazole on pharmacokinetics of ZX-7101A tablets in healthy Chinese subjects.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A scoping review of influenza RdRp-targeting inhibitors: mechanisms, clinical translation, and emerging challenges.Frontiers in microbiology · 2026Review
- Mass balance, excretion, and pharmacokinetics of a single oral dose of [Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: A single-center, open label trial was conducted to evaluate the effects of itraconazole on the pharmacokinetics of ZX-7101A tablets in healthy Chinese adults. Methods: Subjects took a single dose of 40 mg ZX-7101A tablets on Day 1 on Day 31following once-daily itraconazole administration (200 mg, Days 26-50). The concentrations of ZX-7101A and ZX-7101 in plasma samples were determined by liquid chromatography-tandem mass spectrometry. Pharmacokinetic (PK) parameters of ZX-7101A and ZX-7101 were calculated, and the effects of itraconazole on the PK of ZX-7101 were evaluated. Results: The median T Conclusion: The ZX-7101 exposure after coadministration with itraconazole is lower than the exposure after a single dose of 80 mg ZX-7101A tablets. It is therefore not necessary to adjust the dose of ZX-7101A 40 mg when coadministered with itraconazole. Trial registration: http://www.chinadrugtrials.org.cn, identifier: CTR20231556.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.